Core Viewpoint - Altimmune's stock surged approximately 28% following the release of positive results from a 48-week study of its GLP-1 weight-loss drug, pemvidutide, which demonstrated a lower loss of lean mass compared to competing treatments [1][2]. Company Summary - The Phase 2 trial involved 391 participants, with only 21.9% of the weight lost being lean mass, while the remainder was fat loss [2]. - Other GLP-1 drugs have shown that lean mass can account for as much as 40% of total weight loss, highlighting pemvidutide's potential advantage in preserving lean mass [2]. - The CEO of Altimmune emphasized the importance of preserving lean mass for healthy weight loss and physical function [2]. Clinical Results - Participants taking 1.2 mg doses of pemvidutide lost an average of 10.3% of their total weight, while those on 1.8 mg doses lost 11.2%, and those on 2.4 mg doses achieved a mean weight loss of 15.6% [3]. - In contrast, participants receiving placebo doses lost only 2.2% of their weight [3]. Competitive Landscape - Altimmune faces significant competition from established players like Eli Lilly and Novo Nordisk, who are already selling large quantities of GLP-1 drugs [4]. - Additionally, many other companies are developing similar treatments, with 27 new treatments expected to be presented at a recent American Diabetes Association conference [4].

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association's (ADA) 84th Scientific Sessions. "We're pleased with the data presented at ADA that highlight the impressive lean mass prese ...

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “We’re pleased with the data presented at ADA that highlight the impressive lean mass pres ...

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association's (ADA) 84th Scientific Sessions. "Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of ...

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of ...

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT) and reminds investors of the July 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmu ...

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the July 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimm ...

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows: Title:Piper Sandler Virtual Obesity Investor Day  Present ...

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association's (ADA) Scientific Sessions. Details on the fireside chat are as follows: Title:Piper Sandler Virtual Obesity Investor Day  Presente ...

NEW YORK, June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=86302&from=4CLASS PERIOD: December 1, 2023 to April ...